World-renowned lipid therapist Tom Dayspring is back to bringing an update on the current concept of lipidology<\/a> as a follow-up to his five-part audio series from 2018.<\/p>\n\n\n\n In this episode, Tom investigates the growing awareness that atherogenic lipoproteins<\/a> are a major cause of atherosclerotic artery disease<\/a>.TOM highlights Apolipoproat B<\/a> (APOB) and lipoprotein (A)<\/a> (LP (A) and more. He discusses risk assessment, including which lab metrics to use, how to interpret them, and which therapy targets to utilize. Furthermore, Tom highlights the most recent advances in lipid-lowering pharmacological therapy<\/a>, ranging from the continuous evolution of PCSK9<\/a> inhibitors to the most current knowledge of EPA<\/a> and DHA<\/a>, as well as the inclusion of bempedoic acid<\/a> in the list of therapeutic agents.\u00a0<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n During the previous eleven years, Dr. Dayspring has presented over 2500 talks, including over 700 hospital and medical school grand rounds, big CME <\/a>programs in all 50 states, and several additional speaking venues such as teleconferences and webcasts. He wrote a chapter on cholesterol production, absorption, and excretion in the 2008 textbook Therapeutic Lipidology<\/a>, as well as other publications on lipids and lipoproteins, including their pharmacologic regulation and relationships to gender, estrogen<\/a>, and raloxifene<\/a>. He also writes “Lipidaholics Anonymous<\/a>,” a fortnightly email that is distributed to thousands of healthcare professionals. He is a master in PowerPoint and has made several animated presentations, as well as CME<\/a> CDs, relevant to all elements of lipidology and atherosclerosis<\/a>.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n Tom Dayspring at Instagram<\/strong><\/a><\/p>\n\n\n\n Tom Dayspring at Facebook<\/strong><\/a><\/p>\n\n\n\n Tom Dayspring at Twitter<\/strong><\/a><\/p>\n\n\n\n <\/p>\n\n\n\nWorks<\/strong><\/h2>\n\n\n\n
Social Media<\/strong><\/h2>\n\n\n\n